Get the Stockscreener App
114.80
9.06%
9.54
After Hours:
114.50
-0.30
-0.26%
Veradermics Inc stock is traded at $114.80, with a volume of 1.07M.
It is up +9.06% in the last 24 hours and up +78.84% over the past month.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
See More
Previous Close:
$105.26
Open:
$104.99
24h Volume:
1.07M
Relative Volume:
2.03
Market Cap:
$4.76B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-122.13
EPS:
-0.94
Net Cash Flow:
-
1W Performance:
+11.35%
1M Performance:
+78.84%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$104.64
$116.00
1-Week Range:
$95.51
$116.00
52-Week Range:
$32.00
$116.00
Veradermics Inc Stock (MANE) Company Profile
Name
Veradermics Inc
Sector
Industry
Phone
228.372.3376
Address
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
114.80 | 4.37B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | Citigroup | Buy |
| Mar-02-26 | Initiated | Jefferies | Buy |
| Mar-02-26 | Initiated | Leerink Partners | Outperform |
Veradermics Inc Stock (MANE) Latest News
Seven Fleet discloses 80,000 Veradermics (MANE) shares in Form 3 - Stock Titan
Experimental hair loss pill just cleared a major hurdle — when it could hit shelves - New York Post
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill - Yahoo Finance
The week in pharma: action, reaction and insight – week to May 1, 2026 - The Pharma Letter
Veradermics, Inc. Securities Purchase Agreement and Pre-Funded Warrant Details (May 2026) - Minichart
Veradermics Incorporated (MANE) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report - biocentury.com
[8-K] Veradermics, Inc Reports Material Event - Stock Titan
Looking to Regrow Hair? New Options Are on the Horizon - WSJ
Veradermics’ stock grows on pivotal hair loss win - MSN
Is It Too Late To Consider Veradermics (MANE) After A 162% Year To Date Surge? - simplywall.st
Veradermics (MANE) sells 3.84M shares at $100; $300k-warrant PIPE - Stock Titan
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01 - Insider Monkey
[EFFECT] Veradermics, Inc SEC Filing - Stock Titan
A Look At Veradermics (MANE) Valuation After Breakthrough Phase 2/3 Results For Oral Hair Loss Drug - simplywall.st
Veradermics prices $384M stock offering at $100 per share By Investing.com - Investing.com India
Veradermics Announces Pricing of Upsized Public Offering and Private Placement - The National Law Review
Veradermics prices $384M stock offering at $100 per share - Investing.com UK
Veradermics: Closing of Public Offering Isn't Contingent on Private Placement >MANE - Moomoo
Hair-loss drug developer Veradermics prices $384.4M stock sale - Stock Titan
Veradermics announces pricing of upsized public offering and private placement - marketscreener.com
Veradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01 - Sahm
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains - Yahoo Finance
Veradermics announces launch of public offering - MSN
Technical Analysis of Veradermics, Incorporated (NYSE:MANE) - TradingView
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings - Sahm
Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis (NYSE:MANE) - Seeking Alpha
New Oral Drug Shows Success in Reversing Hair Loss - inc.com
Citi Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $120 - Moomoo
Veradermics launches public offering of 3.35 million shares By Investing.com - Investing.com South Africa
Veradermics launches public offering of 3.35 million shares - Investing.com Australia
Veradermics announces offering of 3.35M shares of common stock - TipRanks
Veradermics Announces Launch of Public Offering - WFMZ.com
Veradermics (NYSE: MANE) reports $390.8M preliminary cash and securities - Stock Titan
VDPHL01 hair-loss data and $212.9M capital raise for Veradermics (NYSE: MANE) - Stock Titan
MANE event: Veradermics beats expectations in pattern hair loss trial - BioWorld News
MANE Stock Explodes Higher As Traders Pile Into Breakout - timothysykes.com
How This Biotech Is Taking A Page Out Of Rogaine's Playbook - Investor's Business Daily
MANE Stock Rockets On Breakout As Traders Pile In - StocksToTrade
Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals - TechStock²
Veradermics price target raised to $120 from $85 at Citi - TipRanks
Veradermics (MANE) Stock Rockets On Heavy Momentum - timothysykes.com
Veradermics hair loss pill passes late-stage clinical trial - Yahoo Finance
MANE Stock Rockets On Volatile Breakout Move - StocksToTrade
Veradermics soars on positive data for baldness treatment - BioPharma Dive
Veradermics makes gains on hair loss pill data - The Pharma Letter
Veradermics shares jump 17% on promising hair loss trial results - MSN
A hair-loss pill beat placebo in 519 men, showing growth by Month 2 - Stock Titan
Veradermics Inc Stock (MANE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):